|
|
home > ebr > winter 2022 > pooling efforts to drive gene therapies for rare diseases |
 |
 |
PUBLICATIONS |
European Biopharmaceutical Review
|
When multiple organisations pool their efforts, it promotes affordability and return on investment. Gene therapies, which are expensive and complex to develop and study, and whose target populations are very small, are prime candidates for reaping the benefits of collaboration.
To facilitate cooperation, the US-based Bespoke Gene Therapy Consortium (BGTC) was launched in October 2021, designed to encourage the delivery of more gene therapies for rare diseases. The consortium is headed and funded by the FDA and the National Institutes of Health. Other stakeholders range from large and small biotechs and pharma brands to non-profit organisations.
The Potential to Reduce Costs and Accelerate Approvals
The potential benefits of multiple stakeholders banding together could be significant and provide a model for other markets to follow. If a standardised platform can be agreed, with each drug developer sharing findings and building on what has gone before, the potential to reduce costs and accelerate approvals could be significant. As barriers crumble, new momentum might build as more pharma teams are able to see a clearer path to market. The ultimate beneficiaries will be patients, who could find themselves with access to breakthrough treatments to cure their condition, extend their life expectancy, or improve their quality of life.
|
Read full article from PDF >>
|
 |
 |
 |
Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | |
|
|
 |
News and Press Releases |
 |
Cherwell publishes new guide to EM best practice in compliance with revised Annex 1
Bicester, UK, 26th January 2023: Cherwell, specialists in cleanroom microbiology solutions for the pharmaceutical, healthcare and related industries, has published an update to its guide on “Environmental Monitoring Processes and Validation”, incorporating specific detail on the new version of EU GMP Annex 1. This aims to help sterile medicinal product manufacturers with reviewing and improving their Environmental Monitoring (EM) programs in preparation for compliance with the revised guidelines by August 2023.
More info >> |
|

 |
White Papers |
 |
Using Device Strategy to Drive R&D Productivity
Phillips-Medisize
More info >> |
|
|